Drug Trial Radar · NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Actual
Start
Jul 4, 2025
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Conditions
- Type 2 Diabetes (T2DM)
Interventions
BGM0504Drug
Administered SC
BGM0504Drug
Administered SC
SemaglutideDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Week 0 to Week 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
RSUP Fatmawati
Jakarta, Indonesia
RSUP Persahabatan
Jakarta, Indonesia
RSUPN Dr. Cipto Mangunkusumo
Jakarta, Indonesia
RS Universitas Indonesia
Depok, West Java, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.